Please wait while the formulary information is being retrieved.
KIMMTRAK (tebentafusp-tebn)
- uveal melanoma in HLA-A *02:01 positive patient
100 mcg/0.5 mL intravenous solution
- Infuse 68 mcg over 15-20 minute(s) by intravenous route once weekly
Default screening record
- Infuse 20 mcg over 15-20 minute(s) by intravenous route on day 1 of treatment
- Infuse 30 mcg over 15-20 minute(s) by intravenous route on day 8 of treatment
- Infuse 68 mcg over 15-20 minute(s) by intravenous route on day 15 of treatment
- Infuse 68 mcg over 15-20 minute(s) by intravenous route once weekly
- None
Contraindicated
- None
Severe
Moderate
- None
- Lactation
Contraindicated
- Abnormal hepatic function tests
- Pregnancy
Severe
Moderate
- None
KIMMTRAK (tebentafusp-tebn)
- uveal melanoma in HLA-A *02:01 positive patient
- Cytokine release syndrome
- Hypotension
- Acute abdominal pain
- Chills
- Dry skin
- Edema
- Fatigue
- Fever
- Headache disorder
- Nausea
- Pruritus of skin
- Skin rash
- Vomiting
More Frequent
Severe
Less Severe
- Anemia
- Elevated serum lipase
- Hypertension
- Hypoalbuminemia
- Hypocalcemia
- Hypomagnesemia
- Hypophosphatemia
- Increased alanine transaminase
- Increased aspartate transaminase
- Lymphopenia
- Neutropenic disorder
- Thrombocytopenic disorder
- Alopecia
- Anorexia
- Arthralgia
- Back pain
- Constipation
- Diarrhea
- Dizziness
- Dyschromia
- Dyspnea
- Flu-like symptoms
- Flushing
- Hair discoloration
- Hyperglycemia
- Muscle spasm
- Myalgia
- Night sweats
- Pain in extremities
- Pain in oropharynx
- Paresthesia
- Skin hypopigmentation
- Tachycardia
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- None
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Tebentafusp-tebn
Safety and effectiveness not established in pediatric patients.
- 1 Day – 18 Years
- Safety and effectiveness not established in pediatric patients.
Tebentafusp-tebn
- Severity Level:
D
- Additional Notes: Based on drug pharmacology developmental toxicity is possible.
Contraindicated
Tebentafusp-tebn
Mfr rec to avoid breastfeeding during tx and for 1 week after last dose
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Mfr rec to avoid breastfeeding during tx and for 1 week after last dose |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- Tebentafusp may cause a certain serious (sometimes fatal) side effect known as cytokine release syndrome-CRS. You will be given this medication in a hospital or clinic so your doctor can watch for serious side effects and quickly provide treatment if needed. You will be monitored for at least 16 hours after the first 3 treatments.<br /><br />You will be monitored for at least 30 minutes after later treatments. Tell your doctor right away if you develop symptoms such as fever, chills, headache, nausea, vomiting, stomach/abdominal pain, trouble breathing, skin rash, tiredness, or low blood pressure. If you have side effects, your doctor may temporarily stop or slow down your treatment with this medication. Your doctor may also prescribe other medications before you receive tebentafusp to decrease the risk of side effects.
| Uveal melanoma in HLa-A *02:01 positive patient | |
| C69.3 | Malignant neoplasm of choroid |
| C69.30 | Malignant neoplasm of unspecified choroid |
| C69.31 | Malignant neoplasm of right choroid |
| C69.32 | Malignant neoplasm of left choroid |
| C69.4 | Malignant neoplasm of ciliary body |
| C69.40 | Malignant neoplasm of unspecified ciliary body |
| C69.41 | Malignant neoplasm of right ciliary body |
| C69.42 | Malignant neoplasm of left ciliary body |
| 0-9 | A-Z |
|---|---|
| C69.3 | Malignant neoplasm of choroid |
| C69.30 | Malignant neoplasm of unspecified choroid |
| C69.31 | Malignant neoplasm of right choroid |
| C69.32 | Malignant neoplasm of left choroid |
| C69.4 | Malignant neoplasm of ciliary body |
| C69.40 | Malignant neoplasm of unspecified ciliary body |
| C69.41 | Malignant neoplasm of right ciliary body |
| C69.42 | Malignant neoplasm of left ciliary body |
Formulary Reference Tool